Articles
12 June 2009
Vol. 3 No. 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
https://doi.org/10.4081/hmr.v3i3.568

High-dose CHOP in the rituximab era: still a place?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
220
Views
243
Downloads

Authors

B Coiffier
support@pagepress.org
The combination of rituximab plus CHOP (R-CHOP) has dramatically changed the outcome of patients with diffuse large B-cell lymphoma but there are still eras where the results obtained with RCHOP chemotherapy are not so satisfying. If R-CHOP is associated with 5-year progression-free survival (PFS) and overall survival (OS) of 70% and 80%, respectively, in patients with good risk presentation (IPI score <3), this is not the case in higher risk patients. For elderly patients, increasing the risk of chemotherapy dose is not a possibility because of the potential toxicity; however, this is the case for young patients with adverse prognosis.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



High-dose CHOP in the rituximab era: still a place?. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.568